title: Kidney transplantation and waiting list for renal transplantation for human immunodeficiency virus patients.
abstract: BACKGROUND
  The aim of this study was to evaluate the experience of a renal transplantation unit in the management of human immunodeficiency virus (HIV)-infected patients with end-stage renal disease (ESRD).
  
  
  METHODS
  A prospective study was performed between 2005 and 2010 among 23 patients with ESRD.
  
  
  RESULTS
  In this study 83% of HIV-infected patients with ESRD were included on the waiting list for renal transplantation with 4 patients in a clinical evaluation phase. During the follow-up, 52% of waiting list patients (n = 11) received a renal transplant, and 1 patient underwent a simultaneous kidney-pancreas transplantation. Among the waiting list group we observed a significant later exclusion (43%; n = 3). Among the transplanted group there was a high but clinically inconsequential prevalence of acute tubular necrosis (36%; n = 4) and acute rejection episodes (36%; n = 4). The renal function showed a serum creatinine of 1.1 mg/dL at a follow-up of 24 + 12 months. All patients on the waiting list and after the transplantation are prescribed combined antiretroviral treatment (cART) with a low viral load <50 with CD4 >200.
  
  
  CONCLUSIONS
  HIV-infected patients with ESRD should be considered to be candidates for renal transplantation if they meet the HIV inclusion criteria. Renal transplantation in adequately selected HIV-infected patients is a safe procedure with acceptable patient and graft survivals.
authors.affiliation: Renal Transplantation Unit, Nephrologic Department, Hospital Clínic, University of Barcelona, Barcelona, Spain.
authors.forename: M N
authors.initials: MN
authors.lastname: Martina
authors.forename: F
authors.initials: F
authors.lastname: Cofan
authors.forename: A
authors.initials: A
authors.lastname: Suarez
authors.forename: E
authors.initials: E
authors.lastname: Masso
authors.forename: J C
authors.initials: JC
authors.lastname: Trullas
authors.forename: C
authors.initials: C
authors.lastname: Cervera
authors.forename: A
authors.initials: A
authors.lastname: Moreno
authors.forename: F
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: J M
authors.initials: JM
authors.lastname: Miiro
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000097:blood / Q000276:immunology; D006085:Graft Survival; D015658:HIV Infections / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology / Q000401:mortality; D007683:Kidney Tubular Necrosis, Acute / Q000209:etiology; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011446:Prospective Studies; D013030:Spain; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014850:Waiting Lists / Q000401:mortality
chemical_list: D019380:Anti-HIV Agents; D015415:Biomarkers; D003404:Creatinine